This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Allen, S. Articles by Yacoub, M. Search for Related Content PubMed PubMed Citation Articles by Allen, S. Articles by Yacoub, M.

(Circulation. 1998;97:2406-2413.)
© 1998 American Heart Association, Inc.

Clinical Investigation and Reports

Differential Leukotriene Constrictor Responses in Human Atherosclerotic Coronary Arteries

Sean Allen, PhD; Michael Dashwood, PhD; Karen Morrison, PhD; ; Magdi Yacoub, FRCS

From the Department of Cardiothoracic Surgery (S.A., K.M., M.Y.), Imperial College of Science, Technology & Medicine, Harefield Hospital, Harefield, Middlesex, UK; and Department of Physiology (M.D.), Royal Free Hospital School of Medicine, London, UK.

Correspondence to Professor Sir Magdi H. Yacoub, FRCS, Department of Cardiothoracic Surgery, Imperial College of Science, Technology & Medicine, Heart Science Centre, Harefield Hospital, Hill End Rd, Harefield, Middlesex, UB9 6JH, UK.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Leukotrienes are a class of biologically active lipids that have potent effects on the heart. To assess their role in coronary artery disease, we compared the contractile responses of leukotriene C₄ (LTC₄) and leukotriene D₄ (LTD₄) and their binding activity in both atherosclerotic and nonatherosclerotic human coronary arteries. We also studied expression of the enzymes that control their formation to understand how the 5-lipoxygenase (5-LO) pathway is activated in the coronary arteries.

Methods and Results—The capacity of leukotrienes to affect coronary vessel tone and the influence of atherosclerosis was tested in organ baths. Leukotriene receptors were examined by autoradiography, and antibody binding to the various enzymes responsible for their formation was assessed by use of immunocytochemistry. Nonatherosclerotic coronary artery ring segments were unresponsive to LTC₄ and LTD₄. In contrast, LTC₄ and LTD₄ induced concentration-dependent contractions in atherosclerotic coronary arteries. Specific [³H]-LTC₄ but not LTD₄ binding to atherosclerotic coronary artery was evident, with no evidence of specific binding of [³H]-leukotrienes to nonatherosclerotic coronary artery. High-resolution autoradiography identified specific [³H]-LTC₄ binding sites to smooth muscle cell and to regions of intimal proliferation and plaque. Cells showing positive antibody binding to 5-LO, FLAP (5-lipoxygenase activating protein), and leukotriene A₄ hydrolase were also present in the coronary arteries and had a similar distribution to macrophages.

Conclusions—Atherosclerosis is associated with a specific leukotriene receptor(s) capable of inducing hyperreactivity of human epicardial coronary arteries in response to LTC₄ and LTD₄.

Key Words: atherosclerosis • leukotrienes • coronary disease

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Coronary atherosclerosis is a complex and dynamic multifactorial disease that depends on the exchange of biochemical messages by resident cells (endothelial and smooth muscle cells) and infiltrating leukocytes that regulate functions critical to lesion initiation and progression and to the clinical manifestations of coronary artery disease.¹ The clinical manifestations include stable or unstable angina, acute myocardial infarction, and sudden cardiac death. An episodic increase in vasomotor tone of epicardial coronary arteries is an important pathological component of a number of these ischemic cardiac syndromes; however, its causes remain unclear.^{2 3 4} Infiltrating leukocytes provide a source of a number of vasoactive mediators with the potential to produce these effects.

Leukotrienes are a class of biologically active lipids, synthesized and released from leukocytes, that have a variety of proinflammatory effects.^{5 6} The synthetic pathway for leukotrienes is initiated by the release of arachidonic acid from the cell membrane by phospholipase A₂, followed by its conversion to leukotriene A₄ (LTA₄) by the enzyme 5-LO and its activating protein, FLAP.^{7 8} LTA₄ is either converted to LTB₄ by the enzyme LTA₄ hydrolase^{9 10} or is conjugated with glutathione to form the cysteinyl leukotriene LTC₄.¹¹ The cysteinyl leukotrienes include LTC₄ and its metabolites, LTD₄¹² and LTE₄.¹³

There is a growing body of evidence suggesting a putative role of leukotrienes in coronary heart disease.¹⁴ In particular, the cysteinyl leukotrienes are potent vasoconstrictors of coronary arteries of several species^{15 16 17} and have been shown to be associated with myocardial ischemic events, such as in experimentally induced myocardial infarction¹⁸ and in "cardiac anaphylaxis."¹⁹ In addition, inhibitors of 5-LO²⁰ and cysteinyl leukotriene receptor antagonists²¹ are effective in reducing infarct size and reperfusion-induced arrhythmias in animal models of experimental ischemia. These studies, together with recent clinical evidence of an increased production of cysteinyl leukotrienes in patients with coronary artery disease,^{22 23} implicate involvement of leukotrienes in coronary heart disease. Therefore, to assess their role in coronary artery disease, we compared the contractile responses of LTC₄ and LTD₄ and their binding activity in both atherosclerotic and nonatherosclerotic human coronary arteries. We also studied expression of the enzymes that control their formation to understand how the 5-LO pathway is activated in human coronary arteries.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Materials
LTC₄ and LTD₄ were purchased from Cascade Biochem. [³H]-LTC₄, [³H]-LTD₄, nuclear emulsion (LM-1), and hyperfilm ³H were purchased from Amersham International. Acivicin, L-cysteine, indomethacin 3,3-diaminobenzine tetrahydrocholride, and Tris HCL were purchased from Sigma Chemicals. Rabbit polyclonal antisera to purified 5-LO, FLAP amino acids 41 to 52, and LTA₄ hydrolase were kindly provided by Dr Jilly Evans (Merck Frosst, Pointe Claire-Doval, Canada). Other chemicals were of reagent grade and were obtained from BDH Chemicals.

Patient Details
Human epicardial coronary arteries were removed from explanted hearts of 44 patients at the time of cardiac transplantation. Informed consent was obtained from each patient, and the study was approved by the Harefield Hospital Ethical Committee. Atherosclerotic arteries were obtained from 22 patients with previously diagnosed IHD who had obstructive coronary lesions by angiography (mean age, 57 years; range, 49 to 63). Nonatherosclerotic arteries were obtained from 22 patients undergoing transplantation for reasons other than IHD (mean age, 30 years; range, 4 to 53). The latter group comprised 18 patients with DCM, 3 with congenital heart defects, and 1 with cystic fibrosis. These arteries were free from atheroma on microscopic and histological examination, although they occasionally showed evidence of mild intimal proliferation.

Organ Bath Experiments
LTC₄ and LTD₄ Responses
Left anterior descending and right coronary arteries from both proximal and distal regions of the vessels were dissected free from the surrounding myocardium, cut into ring segments, and mounted for isometric tension recording as described previously.²⁴ In some experiments, ring segments of atherosclerotic arteries were incubated with acivicin (50 µmol/L), an irreversible -glutamyl transpeptidase inhibitor that prevents the metabolism of LTC₄ to LTD₄.^{25 26} In another group of atherosclerotic artery segments, LTD₄ concentration-response curves were performed in the presence of L-cysteine (3 mmol/L) to block the metabolism of LTD₄ to LTE₄.^{26 27}

Endothelial Modulation of LTD₄ Responses
Because LTD₄ can stimulate release of endothelium-derived nitric oxide,²⁸ a separate series of experiments was conducted to investigate whether LTD₄ responses could be affected by the endothelium. Vessels were incubated with indomethacin (10 µmol/L) to block the synthesis of relaxing prostaglandins before the addition of LTD₄. In another group of experiments, vessels were preconstricted with the thromboxane mimetic U46619 (1 to 3 nmol/L) or prostaglandin F₂ (1 mmol/L), whereas in other vessels the endothelium was removed before the tissues were challenged with LTD₄. Removal of the endothelium was confirmed by the absence of relaxation to the endothelium-dependent relaxation factor substance P.

In Vitro Receptor Autoradiography
Epicardial coronary arteries were obtained from six patients undergoing heart transplantation (three DCM and three IHD) and snap-frozen in liquid nitrogen. Tritiated leukotriene binding sites in atherosclerotic and nonatherosclerotic coronary arteries were localized with the use of in vitro receptor autoradiography. The optimum incubation time (association experiments) and wash times (dissociation experiments) had been determined previously.^{26 28} Saturation studies were performed on slide-mounted sections of both vessel types that were initially preincubated in 50 mmol/L Tris HCl buffer, pH 7.4, for 15 minutes at 4°C to reduce levels of endogenous leukotrienes. Slides were then incubated in buffer containing 5 mmol/L CaCl₂, 0.05 mmol/L acivicin, and 20 mmol/L L-cysteine in the presence of 0.1 to 3.0 nmol/L [³H]-LTC₄ or [³H]-LTD₄ (specific activity, 154 Ci/mmol) for 60 minutes at 4°C. Acivicin was used to prevent the metabolism of LTC₄ to LTD₄ during the incubation, and L-cysteine prevented the metabolism of LTD₄ to LTE₄. The degree of nonspecific binding was established by incubating alternate sections in the presence of 1 µmol/L unlabelled LTC₄ and LTD₄. After incubation, sections were washed twice for 5 minutes in buffer at 4°C, dipped in cold (4°C) distilled water, and dried in a stream of cold air. Low- and high-resolution autoradiography was performed as described previously^{26 28} by exposing incubated sections to hyperfilm ³H for 5 weeks and apposing sections to coverslips coated with emulsion for 6 weeks in lightproof boxes at 4°C, respectively. Estimation of [³H]-LTC₄ and [³H]-LTD₄ binding was performed by wiping off tissue sections from the microscope slides with Nucwipes (National Diagnostic), which were then placed in Ultragold scintillant (4.5 mL) and counted for tritium as described previously.²⁶

Immunocytochemistry of 5-LO, FLAP, and LTA₄Hydrolase
The left anterior descending arteries from eight hearts were obtained from patients undergoing transplantation (five DCM and three IHD). Frozen sections 6-µm thick were cut, and rabbit anti-5LO (diluted 1:400), rabbit anti-FLAP (diluted 1:300), rabbit anti-LTA₄ hydrolase (diluted 1:1200), or mouse monoclonal anti-CD68 (diluted 1:1000) was applied to the sections, which were incubated for 1 hour. Tissues were then stained according to the manufacturer's instructions.

Data Analysis
Contractions were measured as a percentage of the maximal isometric contraction to 90 mmol/L KCl. The E_max value refers to the maximum response at the highest dose of leukotriene, and the EC₅₀ value for each concentration-effect curve was obtained by linear regression analysis of data points in grams or percentage of KCl response versus log concentration above and below the EC₅₀ level. These values were transformed into pD₂ values (-log EC₅₀). All results are shown as mean±SEM, and in all experiments, n equals the number of patients from whom the vessels were obtained. Differences between leukotrienes were compared by unpaired Student's t test. Comparisons between control and experimental groups were made by ANOVA followed by a Bonferroni correction. A value of P<.05 was considered a statistical difference.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Effect of LTC₄ and LTD₄ on Vasomotor Tone
Nonatherosclerotic coronary artery ring segments were unresponsive to LTC₄ and LTD₄ from each of the three nonatherosclerotic groups (Figure 1; n=8). In contrast, LTC₄ and LTD₄ induced concentration-dependent contractions in atherosclerotic coronary arteries (Figure 1; n=11). The potency (EC₅₀) and maximum response (E_max) to LTC₄ were 11.1 nmol/L (95% CI, 9.4 to 13.0) and 62±8.4%, respectively, and EC₅₀ and E_max for LTD₄ were 7.0 nmol/L (95% CI, 1.3 to 36) and 32±6.5%, respectively (P<.05, E_max for LTC₄ versus LTD₄). The degree of contraction of the atherosclerotic vessels induced by LTC₄ and LTD₄ after pretreatment with indomethacin was unchanged, indicating that constricting prostaglandins such as thromboxane A₂ were not involved (data not shown). Furthermore, responses to each leukotriene were prolonged (usually 20 to 30 minutes for each concentration response to plateau) and difficult to wash out. Vessel segments treated with vehicle (MeOH:H₂O:AcOH) to control for the solvent that the leukotrienes were dissolved in had no effect on basal vessel tone (0 mN above baseline, n=6), indicating that the contractions were due to the leukotriene and not to the solvent. The unresponsiveness of the nonatherosclerotic arteries was specific to the leukotrienes and not due to damage of the vessels, because both thromboxane A₂ and serotonin produced contractions in the same coronary arteries (data not shown).

View larger version (15K): [in this window] [in a new window]   Figure 1. Leukotriene contractions in human atherosclerotic (solid symbols) and nonatherosclerotic (open symbols) epicardial coronary arteries. The curves show the contractions elicited by LTC4 (open circles, n=8; solid circles, n=11) and LTD4 (open squares, n=8; solid squares, n=11). The response is presented as a percentage of the response to 90 mmol/L KCl. All values are mean±SEM. (Emax values for LTC4 versus LTD4 [solid symbols], P<.05).

Influence of Endothelium-Dependent Relaxing Factors on LTD₄ Responses
In the presence of indomethacin or in vessel segments in which the endothelium had been removed, nonatherosclerotic coronary arteries remained unresponsive to LTD₄ (0 mN, n=6). When nonatherosclerotic arteries were preconstricted with the thromboxane analogue U46619 or prostaglandin F₂, LTD₄ (1 pmol/L to 0.1 µmol/L) failed to induce relaxations in the arteries (data not shown). The fact that there were no relaxation responses to LTD₄ was not because of damage to the endothelium, because the endothelium-dependent vasodilator substance P (10 nmol/L) induced relaxations in preconstricted coronary artery segments (data not shown). These results confirm our previous findings, which showed that LTC₄ responses in atherosclerotic coronary arteries were not influenced by the endothelium.²⁴

Low-Resolution Autoradiography of Atherosclerotic and Nonatherosclerotic Coronary Arteries
Qualitative low-resolution autoradiography images showed evidence of [³H]-LTC₄ (top) and [³H]-LTD₄ (bottom) binding to both atherosclerotic and nonatherosclerotic coronary arteries (Figure 2). In atherosclerotic vessels, tritiated LTC₄ appeared to show the greatest amount of binding at 1 nmol/L. In both nonatherosclerotic and atherosclerotic arteries, the degree of nonspecific binding (in the presence of excess unlabelled leukotriene) was high (50% to 80%), particularly at 3 nmol/L. To quantitatively assess the degree of specific binding to establish any differences in the amount of binding in the two vessel types (particularly at the low concentrations in which binding was too low to image), we estimated the amount of binding to both vessels by counting tritium levels. Counts of [³H]-LT showed a significant degree of specific [³H]-LTC₄ binding to atherosclerotic coronary artery (Figure 3, upper panel, 0.3 and 1.0 nmol/L; P<.05), with no evidence of concentration-dependent specific binding of [³H]-LTC₄ to nonatherosclerotic coronary artery (Figure 3, lower panel). Similarly, no significant concentration-dependent [³H]-LTD₄ specific binding was evident in atherosclerotic (Figure 4, upper panel) or nonatherosclerotic vessels (Figure 4, lower panel).

View larger version (42K): [in this window] [in a new window]   Figure 2. Representative low-resolution autoradiography images of tritiated LTC4 and LTD4 to human atherosclerotic (top) and nonatherosclerotic (bottom) epicardial coronary arteries. Total (TOT) [3H]-LTC4 or [3H]-LTD4 was achieved by incubating coronary artery segments in increasing (left to right) concentrations of radiolabeled leukotriene (0.3 to 3.0 nmol/L). Nonspecific binding (NSB) was obtained by incubating tissue in the presence of an excess of unlabelled leukotriene (1 µmol/L). Scale bar, 1 mm.

View larger version (16K): [in this window] [in a new window]   Figure 3. Analysis of [3H]-LTC4 binding to human atherosclerotic (top) and nonatherosclerotic (bottom) epicardial coronary arteries. Coronary artery segments were incubated with [3H]-LTC4 (0.1 to 3.0 nmol/L) for 60 minutes at 4°C in a final volume of 10 µL. Nonspecific binding was determined in the presence of an excess of unlabelled LTC4 (1 µmol/L). Specific binding (solid circles) was determined by subtracting nonspecific binding (solid squares) from total binding (solid triangles). Each point represents the mean of 12 preparations from three patients. Significant specific binding for LTC4 occurred at 0.3 and 1.0 nmol/L (P<.05).

View larger version (12K): [in this window] [in a new window]   Figure 4. Analysis of [3H]-LTD4 binding to human atherosclerotic (top) and nonatherosclerotic (bottom) epicardial coronary arteries. Coronary artery segments were incubated with [3H]-LTD4 (0.1 to 3.0 nmol/L) for 60 minutes at 4°C in a final volume of 10 µL. Nonspecific binding was determined in the presence of an excess of unlabelled LTD4 (1 µmol/L). Specific binding (solid circles) was determined by subtracting nonspecific binding (solid squares) from total binding (solid triangles). Each point represents the mean of 12 preparations from three patients.

High-Resolution Autoradiography of Atherosclerotic Coronary Arteries
Because LTC₄ was the only leukotriene that showed significant specific binding in atherosclerotic coronary arteries, we used high-resolution autoradiography to identify the cell types to which LTC₄ was binding. High-resolution images of atherosclerotic vessels showed dense [³H]-LTC₄ binding that was mainly localized to the medial smooth muscle cells, with less binding to adventitia (data not shown). In atherosclerotic coronary arteries, there was also additional binding to regions of intimal proliferation and very dense binding to areas of plaque (Figure 5). There was no evidence of [³H]-LTC₄ binding to the endothelium.

View larger version (88K): [in this window] [in a new window]   Figure 5. High-resolution autoradiography image shows (A) section of an atherosclerotic coronary artery stained with hematoxylin and eosin. Top arrow in A indicates high-density [3H]-LTC4 binding to calcified plaque, shown in B; C, corresponding underlying stained tissue. Bottom arrow in panel A indicates high-density [3H]-LTC4 binding to plaque debris, shown in D; E, underlying stained tissue. Scale bar, 100 µm.

5-LO, FLAP, and LTA₄ Hydrolase Expression in Human Coronary Arteries
Immunocytochemical staining demonstrated macrophages in the adventitia of nonatherosclerotic vessel segments (Figure 6), with greater numbers in the atherosclerotic vessels (data not shown). In addition, some macrophages were also present in the media, whereas areas of intimal proliferation associated with the atherosclerotic coronary arteries were abundant with macrophages (Figure 7). Generally increased numbers were seen in the intima with increasing severity of disease. The more-advanced diseased arteries also had a few macrophages in the media. Cells positive for 5-LO, FLAP, and LTA₄ hydrolase were also seen in the adventitia and in areas of intimal proliferation that corresponded to the distribution of the macrophages (Figure 7). In these areas, 5-LO labeled the greatest number of cells, with FLAP present in a smaller percentage and LTA₄ hydrolase generally demonstrating the least number of positive cells. All negative control sections had no staining. Thus, compared with the nonatherosclerotic vessels (Figure 6), atherosclerotic arteries (Figure 7) contained a greater number of infiltrating macrophages and hence a greater amount of enzymatic machinery to produce leukotrienes. An unexpected finding was that the medial smooth muscle cells of both vessel types were also positive with all three leukotriene antibodies to a similar extent (Figures 6 and 7). In preliminary experiments, we also found some positive staining for 5-LO, FLAP, and LTA₄ hydrolase in the cultured smooth muscle cells derived from human coronary arteries (data not shown). The degree of positive staining was variable between smooth muscle cell cultures derived from different patients.

View larger version (70K): [in this window] [in a new window]   Figure 6. Photomicrographs of consecutive sections of a human nonatherosclerotic coronary artery stained for (a) macrophages (CD68), (b) 5-LO, (c) FLAP, (d) LTA4 hydrolase, and (e) negative control. There are a few macrophages in the adventitia but none in the media (M). There are also a few cells in the adventitia staining positively for each leukotriene antibody (b–d). Note the strong positive staining of 5-LO, FLAP, and LTA4 hydrolase in the medial smooth muscle. L indicates lumen.

View larger version (72K): [in this window] [in a new window]   Figure 7. Photomicrographs of consecutive sections of a human atherosclerotic coronary artery with advanced intimal proliferation stained for (a) macrophages (CD68), (b) 5-LO, (c) FLAP, (d) LTA4 hydrolase, and (e) negative control. Areas of intimal thickening contained abundant macrophages. Similar staining patterns are also seen for the leukotrienes (b–d). Note the strong positive staining of 5-LO, FLAP, and LTA4 hydrolase in the medial smooth muscle. L indicates lumen.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
These results show for the first time that the presence of atherosclerosis in human coronary arteries specifically augments contractions to cysteinyl leukotrienes and provides an enzymatic capacity within the vessel wall in the form of infiltrating macrophages and possibly smooth muscle cells to produce leukotrienes that could contribute to the hyperreactivity of atherosclerotic vessels. Hyperreactivity of human atherosclerotic coronary arteries to LTC₄ and LTD₄ was unaffected by endothelium-derived mediators. Previous reports²⁹ have shown increased responsiveness of atherosclerotic arteries to serotonin that was unaffected by the endothelium. In those studies, hyperreactivity was reported to involve an increased responsiveness of the receptor or signal transduction system that was not apparent in the receptors present in the nondiseased arteries. Our present findings provide no evidence of cysteinyl leukotriene receptors in nonatherosclerotic epicardial coronary arteries, as suggested by the inability to contract to LTC₄ or LTD₄ and confirmed by the absence of a significant number of specific [³H]-leukotriene binding sites. In contrast, atherosclerotic vessels responded with potent contractions to LTC₄ and with smaller contractions to LTD₄, and a significant number of specific [³H]-LTC₄ binding sites were present in the atherosclerotic vessels. These results confirm and extend our previous findings²⁴ and suggest a novel mechanism whereby specific leukotriene receptors associated with atherosclerotic vessels may explain the augmented response to these leukotrienes.

There was considerable variation of specific [³H]-LTC₄ and [³H]-LTD₄ binding sites among the tissues, with only atherosclerotic coronary arteries exhibiting significant specific, concentration-dependent [³H]-LTC₄ binding. Other studies³⁰ have failed to detect any [³H]-LTD₄ binding to dog aorta and bovine coronary artery, although [³H]-LTC₄ bound at a relatively high level. Using [³H]-LTC₄, several other studies have demonstrated the existence of a specific LTC₄ binding site in membrane preparations of guinea pig,³⁰ rat,³¹ and human lung.³² However, these data are difficult to interpret owing to a large number of independent LTC₄ specific binding sites reported to be present in the membranes under investigation. The relevance of the LTC₄ binding sites is still unclear, with results from many groups supporting the conclusions of an early report³³ describing glutathione-S-transferase as the LTC₄ binding protein. It is possible that a percentage of LTC₄ and LTD₄ binding in atherosclerotic and nonatherosclerotic vessels, particularly at 3 nmol/L (which showed the highest degree on nonspecific binding), may be attributable to nonspecific binding to nonreceptor proteins such as glutathione-S-transferase. Nonetheless, our functional and binding data suggest that LTC₄- and LTD₄-induced contractions of atherosclerotic coronary arteries occur via a leukotriene binding site specific for LTC₄. Future functional and binding studies, using competition assays with different structural classes of leukotriene antagonists, should clarify whether these binding sites in atherosclerotic coronary arteries represent a distinct LTC₄ receptor.

Examination of high-resolution autoradiographs of atherosclerotic coronary arteries revealed dense [³H]-LTC₄ binding to the medial smooth muscle cells and regions of intimal proliferation and plaque formation. This is interesting in light of the recent work of Brezinski et al,³⁴ who showed that angioplasty triggers intracoronary leukotriene production and who suggested that plaque rupture may be the stimulus triggering the appearance of these vasoactive compounds and that they may be derived from the atherosclerotic plaque itself or from the interaction of the released plaque debris with peripheral blood cells. There is now evidence that localized chronic inflammatory processes within the atherosclerotic plaque, rather than the endothelium, are responsible not only for plaque rupture itself but also for the hyperreactivity of these vessels to vasoconstrictor stimuli.³⁵ The enhanced reactivity of the epicardial coronary arteries from IHD patients observed here, together with the evidence of leukotriene binding to plaque, appears to suggest that a local or systemic release of leukotrienes in response to tissue injury might contribute to spasm of a coronary vessel segment and/or precipitate a plaque rupture.

Human coronary arteries not only have the ability to contract to leukotrienes, they also have the capacity to produce leukotrienes. Previous work³⁶ has shown that human and canine coronary arteries can produce leukotrienes when stimulated with calcium ionophore or treated with arachidonic acid. In the present study, we identified staining of 5-LO, FLAP, and LTA₄ hydrolase that appeared to be associated with macrophages. The amount of staining for each leukotriene protein was increased in the atherosclerotic vessels and appeared to correlate with the presence of increased numbers of macrophages.

Monocyte/macrophage recruitment to the vascular intima followed by foam cell transformation is a crucial early step in the development of atherosclerosis, and there is increased evidence that leukotrienes can play a role in this process. For example, 5-LO inhibitors can prevent the uptake of cholesterol esters into monocytes and macrophages in vitro.³⁷ In addition, oxidized LDL can increase 5-LO activity in a mononuclear cell line,³⁸ suggesting that in vivo oxidized LDL may play an important role in the upregulation of the 5-LO pathway. This is important because LDL is known to stimulate leukotriene production in monocytes.³⁹ Furthermore, we have recent data to suggest that there is an overproduction of LTB₄ in patients with hypercholesterolemia (unpublished data from our laboratory, 1998). Leukotriene B₄ is chemotactic for monocytes⁴⁰ and can cause increased adhesion of leukocytes to the vascular endothelium.⁴¹ Taken together, the above evidence suggests that activation of the macrophage 5-LO pathway may play an important role in the inflammatory response associated with migration and transformation into foam cells of macrophages within the vessel intima. The importance of the 5-LO pathway in inflammation has recently been highlighted in 5-LO and FLAP knockout mice⁴² in studies that showed a blunted inflammatory response to topical arachidonic acid and platelet activating factor–induced shock compared with controls.

In conclusion, we present evidence of a novel mechanism in which atherosclerosis is associated with the appearance of a leukotriene receptor(s) capable of inducing hyperreactivity of human epicardial coronary arteries in response to LTC₄ and LTD₄. Because heart tissue has the capacity to both produce and respond to leukotrienes and because patients with coronary artery disease have raised levels of leukotrienes, the present findings suggest that endogenous leukotrienes may play an important role in the pathogenesis and clinical manifestations of atherosclerosis.

	Selected Abbreviations and Acronyms

 

DCM = dilated cardiomyopathy FLAP = 5-lipoxygenase activating protein IHD = ischemic heart disease 5-LO = 5-lipoxygenase LT = leukotriene

Received November 24, 1997; revision received February 9, 1998; accepted February 13, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(suppl II):II-3–II-16.

2. Oliva PB, Breckinridge JC. Arteriographic evidence of coronary arterial spasm as a cause of exercise-induced ST-segment elevation in patients with variant angina. Circulation. 1979;59:948–954.[Abstract/Free Full Text]

3. Maseri A, Davies G, Huckett D, Kaski JC. Coronary artery spasm and vasoconstriction: the case for a distinction. Circulation. 1990;81:1983–1991.[Free Full Text]

4. Epstein SE, Talbot TL. Dynamic coronary tone in precipitation, exacerbation and relief of angina pectoris. Am J Cardiol. 1981;48:797–803.[Medline] [Order article via Infotrieve]

5. Ford-Hutchinson AW. Leukotriene B₄ in inflammation. Crit Rev Immunol. 1990;10:1–14.[Medline] [Order article via Infotrieve]

6. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1980;220:568–575.

7. Soberman RJ, Harper TW, Betteridge D, Lewis RA, Austen KF. Characterization and separation of the arachidonic acid 5-lipoxygenase and linoleic acid omega-6 lipoxygenase (arachidonic acid 15-lipoxygenase) of human polymorphonuclear leukocytes. J Biol Chem. 1985;260:4508–4518.[Abstract/Free Full Text]

8. Rouzer CA, Samuelsson B. On the nature of the 5-lipoxygenase reaction in human leukocytes: enzyme purification and requirement for multiple stimulatory factors. Proc Natl Acad Sci U S A. 1985;82:6040–6044.[Abstract/Free Full Text]

9. Borgeat P, Samuelsson B. Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes: formation of a novel dihydroxyeicosatetraenoic acid. J Biol Chem. 1979;254:2643–2646.[Abstract/Free Full Text]

10. Corey EJ, Marfat A, Goto G, Brion F. Leukotriene B₄: total synthesis and assignment of stereochemistry. J Am Chem Soc. 1980;102:7984–7985.

11. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A. 1979;76:4275–4279.[Abstract/Free Full Text]

12. Morris HR, Taylor GW, Piper PJ, Tippins JR. Structure of slow-reacting substance of anaphylaxis from guinea pig lung. Nature. 1980;285:104–106.[Medline] [Order article via Infotrieve]

13. Lewis RA, Drazen JM, Austen KF, Clark DA, Corey EJ. Identification of the C (6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A): importance of the 11-cis geometry for biological activity. Biochem Biophys Res Commun. 1980;96:271–277.[Medline] [Order article via Infotrieve]

14. Allen SP, Yacoub MH. Role of leukotrienes in coronary artery surgery. Curr Opin Cardiol. 1995;10:605–613.[Medline] [Order article via Infotrieve]

15. Burke JA, Levi R, Guoz G, Corey EJ. Leukotriene C₄, D₄ and E₄: effects on human and guinea pig cardiac preparations in vitro. J Pharmacol Exp Ther. 1981;221:235–241.[Abstract/Free Full Text]

16. Roth DM, Lefer AM. Studies on the mechanism of leukotriene induced coronary artery constriction. Prostaglandins. 1983;26:573–581.[Medline] [Order article via Infotrieve]

17. Wargovich T, Mehta J, Nichols WW, Pepine CJ, Conti R. Reduction in blood flow in normal and narrowed coronary arteries of dogs by leukotriene C₄. J Am Coll Cardiol. 1985;6:1047–1051.[Abstract]

18. Evers AS, Murphee S, Suffitz JE, Jakschik BA, Needleman P. Effects of endogenously produced leukotrienes, thromboxane, and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. J Clin Invest. 1985;75:992–999.

19. Levi R. Cardiac anaphylaxis: models, mediators, mechanisms, and clinical consideration. In: Marone IG, Lichtensein LM, Condorelli M, Fanci AS, eds. Human Inflammatory Disease: Clinical Immunology I. Toronto: BC Decker; 1988:93–105.

20. Lepran I, Lefer AM. Protective actions of propyl gallate, lipoxygenase inhibitor, on the ischemic myocardium. Circ Shock. 1985;15:79–88.[Medline] [Order article via Infotrieve]

21. Hock CE, Beck LD, Papa LA. Peptide leukotriene receptor antagonism in myocardial ischemia and reperfusion. Cardiovasc Res. 1992;26:1206–1211.[Abstract/Free Full Text]

22. Allen SP, Sampson AP, Piper PJ, Chester AH, Ohri SK, Yacoub MH. Enhanced excretion of urinary leukotriene E₄ in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis. 1993;4:899–904.[Medline] [Order article via Infotrieve]

23. Carry M, Korby V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. Circulation. 1992;85:230–236.[Abstract/Free Full Text]

24. Allen SP, Dashwood MR, Chester AH, Tadjkarimi S, Collins M, Piper PJ, Yacoub MH. Influence of atherosclerosis on the vascular reactivity of isolated epicardial coronary arteries to leukotriene C4. Cardioscience. 1993;4:47–54.[Medline] [Order article via Infotrieve]

25. Allen L, Meck R, Yunis A. The inhibition of -glutamyl transpeptidase from human pancreatic carcinoma cells by -amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT125) NSC-163501. Res Commun Chem Pathol Pharmacol. 1980;27:175–182.[Medline] [Order article via Infotrieve]

26. Allen SP, Chester AH, Dashwood MR, Tadjkarimi S, Piper PJ, Yacoub MH. Preferential vasoconstriction to cysteinyl leukotrienes in the human saphenous vein compared with the internal mammary artery: implications for graft performance. Circulation. 1994;90:515–524.[Abstract/Free Full Text]

27. Shirley JT, Cheng JB. Competition of leukotrienes and ICI-198615 for [³H]-LTD₄ binding sites in guinea pig lung membranes suggests the involvement of two LTD₄ receptor subtypes. J Pharmacol Exp Ther. 1991;258:531–536.[Abstract/Free Full Text]

28. Allen SP, Chester AH, Piper PJ, Sampson AP, Akl SK, Yacoub MH. Effects of leukotrienes C₄ and D₄ on human isolated saphenous veins. Br J Clin Pharmacol. 1992;34:409–414.[Medline] [Order article via Infotrieve]

29. Tagawa H, Tomoike H, Mitsuoka W, Satoh S, Kuga T, Shimokawa H, Nakamura M, Takeshita A. Hyperreactivity of aortic smooth muscle to serotonin is related to the presence of atheroma in Watanabe heritable hyperlipidaemic rabbits. Cardiovasc Res. 1993;27:2164–2169.[Abstract/Free Full Text]

30. Cheng JB, Lang D, Bewtra A, Townley RG. Tissue distribution and functional correlation of ³H leukotriene C₄ and ³H D₄ binding sites in guinea pig ileum and lung preparations. J Pharmacol Exp Ther. 1985;232:80–87.[Abstract/Free Full Text]

31. Pong SS, DeHaven RN, Kuehl FA Jr, Egan RW. Leukotriene C₄ binding to rat lung membranes. J Biol Chem. 1983b;258:9616–9619.

32. Rovati GE, Oliva D, Sautebin L, Folco GC, Welton AF, Nicosia S. Identification of specific binding sites for leukotriene C₄ in membranes from human lung. Biochem Pharmacol. 1985;34:2831–2837.[Medline] [Order article via Infotrieve]

33. Sun FE, Chau LY, Spur B, Corey EJ, Lewis RA, Austen KF. Identification of a high affinity leukotriene C₄ binding protein in rat liver cytosol as glutathione-S-transferase. J Biol Chem. 1986;261:8540–8546.[Abstract/Free Full Text]

34. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary leukotrienes and lipoxin A₄: impact of aspirin therapy. Circulation. 1992;86:56–63.[Abstract/Free Full Text]

35. Zeiher AM, Geobel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 1995;91:941–947.[Abstract/Free Full Text]

36. Piomelli D, Feinmark SJ, Cannon PJ. Leukotriene biosynthesis by canine and human coronary arteries. J Pharmacol Exp Ther. 1987;241:763–767.[Abstract/Free Full Text]

37. Schroeff JG, Havekes L, Weerhem AM, Emeis JJ, Vermeer BJ. Suppression of cholesteryl ester accumulation in cultured human monocyte-derived macrophages by lipoxygenase inhibitors. Biochem Biophys Res Commun. 1985;127:366–372.[Medline] [Order article via Infotrieve]

38. Fair A, Pritchard KAJ. Oxidized low density lipoprotein increases U937 cell 5-lipoxygenase activating protein. Biochem Biophys Res Commun. 1994;201:1014–1020.[Medline] [Order article via Infotrieve]

39. Salbach PB, Specht E, von Hodenberg E, Kossmann J, Janssen-Timmer U, Schneider WJ, Hugger P, King WC, Glomset JA, Habenicht AJR. Differential low density lipoprotein receptor-dependent formation of eicosanoids in human blood-derived monocytes. Proc Natl Acad Sci U S A. 1992;89:2439–2443.[Abstract/Free Full Text]

40. Lee TH, Austen KF. Arachidonic acid metabolism by the 5-lipoxygenase pathway, and the effects of alternative dietary fatty acids. Adv Immunol. 1986;39:145–175.[Medline] [Order article via Infotrieve]

41. Tonnesen MG, Anderson DC, Springer TA, Knedler A, Avdi N, Henson PM. Adherence of neutrophils to cultured human microvascular endothelial cells: stimulation by chemotactic peptides and lipid mediators and dependence upon the Mac-1, LFA-1, gp150,95 glycoprotein family. J Clin Invest. 1989;83:637–646.

42. Byrum RS, Goulet JL, Griffiths RJ, Koller BH. Role of the 5-lipoxygenase protein (FLAP) in murine acute inflammatory responses. J Exp Med. 1997;6:1065–1075.We compared the contractile responses and binding activity of leukotrienes (LT) C₄ and D₄ in both atherosclerotic and nonatherosclerotic coronary arteries and examined expression of the enzymes responsible for their formation. Nonatherosclerotic coronary artery ring segments were unresponsive to LTC₄ and LTD₄. In contrast, LTC₄ and LTD₄ induced concentration-dependent contractions in atherosclerotic coronary arteries. There was a high degree of specific [³H]-LTC₄ binding to atherosclerotic coronary artery, with no evidence of specific binding of leukotrienes to nonatherosclerotic coronary artery. Positive antibody binding to 5-lipoxygenase, 5-lipoxygenase activating protein (FLAP), and LTA₄ hydrolase was also present in the coronary arteries.

This article has been cited by other articles:

				J. J. Freiberg, A. Tybjaerg-Hansen, H. Sillesen, G. B. Jensen, and B. G. Nordestgaard Promotor Polymorphisms in Leukotriene C4 Synthase and Risk of Ischemic Cerebrovascular Disease Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 990 - 996. [Abstract] [Full Text] [PDF]

				M. Mehrabian and H. Allayee Vascular Cross-Talk: A Conversation Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1748 - 1749. [Full Text] [PDF]

				J. H. Dwyer, H. Allayee, K. M. Dwyer, J. Fan, H. Wu, R. Mar, A. J. Lusis, and M. Mehrabian Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis N. Engl. J. Med., January 1, 2004; 350(1): 29 - 37. [Abstract] [Full Text] [PDF]

				P. Liu, D. A. Misurski, and V. Gopalakrishnan Cysteinyl leukotriene-dependent [Ca2+]i responses to angiotensin II in cardiomyocytes Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1269 - H1276. [Abstract] [Full Text] [PDF]

				C. Brink, S.-E. Dahlen, J. Drazen, J. F. Evans, D. W. P. Hay, S. Nicosia, C. N. Serhan, T. Shimizu, and T. Yokomizo International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors Pharmacol. Rev., March 1, 2003; 55(1): 195 - 227. [Abstract] [Full Text] [PDF]

				R. Spanbroek, R. Grabner, K. Lotzer, M. Hildner, A. Urbach, K. Ruhling, M. P. W. Moos, B. Kaiser, T. U. Cohnert, T. Wahlers, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis PNAS, February 4, 2003; 100(3): 1238 - 1243. [Abstract] [Full Text] [PDF]

				S. Simula, E. Vanninen, L. Viitanen, A. Kareinen, S. Lehto, P. Pajunen, M. Syvanne, J. Kuikka, M. Laakso, and J. Hartikainen Cardiac Adrenergic Innervation Is Affected in Asymptomatic Subjects with Very Early Stage of Coronary Artery Disease J. Nucl. Med., January 1, 2002; 43(1): 1 - 7. [Abstract] [Full Text] [PDF]

				G. Hardy, F. Stanke-Labesque, M. Peoc'h, A. Hakim, P. Devillier, F. Caron, S. Morel, P. Faure, S. Halimi, and G. Bessard Cysteinyl Leukotrienes Modulate Angiotensin II Constrictor Effects on Aortas From Streptozotocin-Induced Diabetic Rats Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1751 - 1758. [Abstract] [Full Text] [PDF]

				F. Stanke-Labesque, P. Devillier, S. Veitl, F. Caron, J.-L. Cracowski, and G. Bessard Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats Cardiovasc Res, January 1, 2001; 49(1): 152 - 160. [Abstract] [Full Text] [PDF]

				R. M. Fleming and L. B. Boyd The Effect of High-Protein Diets on Coronary Blood Flow Angiology, October 1, 2000; 51(10): 817 - 826. [Abstract] [PDF]

				P. Laine, A. Naukkarinen, L. Heikkila, A. Penttila, and P. T. Kovanen Adventitial Mast Cells Connect With Sensory Nerve Fibers in Atherosclerotic Coronary Arteries Circulation, April 11, 2000; 101(14): 1665 - 1669. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Allen, S. Articles by Yacoub, M. Search for Related Content PubMed PubMed Citation Articles by Allen, S. Articles by Yacoub, M.